News Archive


Angiotech Pharmaceuticals, Inc. announces transaction with Johnson & Johnson relating to Angiotech's Quill technology

Angiotech Pharmaceuticals, Inc. ("Angiotech") announced today that it had concluded the sale of certain Quill intellectual property to Ethicon, Inc. ("Ethicon"), a unit of Johnson & Johnson, Inc., and its affiliates. Under the terms of the transaction, Angiotech will retain worldwide rights to manufacture, market and sell Quill wound closure products.